サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536194

自己免疫性溶血性貧血治療薬の世界市場

Autoimmune Hemolytic Anemia Therapeutics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 197 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
自己免疫性溶血性貧血治療薬の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

自己免疫性溶血性貧血治療薬の世界市場は2030年までに8億7,370万米ドルに達する見込み

2023年に5億3,560万米ドルと推定される自己免疫性溶血性貧血治療薬の世界市場は、2030年には8億7,370万米ドルに達し、分析期間2023～2030年のCAGRは7.2%で成長すると予測されます。本レポートで分析したセグメントの一つである副腎皮質ステロイドは、CAGR 8.0%を記録し、分析期間終了時には5億910万米ドルに達すると予測されます。モノクローナル抗体分野の成長率は、分析期間中CAGR 6.9％と推定されます。

米国市場は1億4,590万米ドルと推定、中国はCAGR 11.7%で成長すると予測

米国の自己免疫性溶血性貧血治療薬市場は、2023年に1億4,590万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 11.7%で推移し、2030年には1億9,470万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と7.2%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の自己免疫性溶血性貧血治療薬市場- 主要促進要因と動向まとめ

自己免疫性溶血性貧血（AIHA）治療薬は、免疫系が誤って体内の赤血球を攻撃・破壊してしまう稀な疾患であるAIHAの症状を管理・緩和することを目的とした一連の治療を包含します。これにより、疲労、顔面蒼白、息切れ、黄疸を特徴とする溶血性貧血が引き起こされます。治療法としては、副腎皮質ステロイド、免疫抑制剤、モノクローナル抗体、輸血などの支持療法があります。これらの治療薬の主な目的は、赤血球破壊率を低下させ、免疫反応を管理し、症状に対処して患者のQOLを改善することです。

近年、AIHAの病態生理と免疫機構に対する理解が深まったことにより、AIHA治療薬の開発が大きく進展しています。プレドニゾンのような副腎皮質ステロイドは、炎症と免疫活性を抑える効果があるため、しばしば治療の第一選択薬となります。しかし、長期間の使用は副作用を引き起こす可能性があり、代替療法の必要性を促しています。B細胞上のCD20を標的とするモノクローナル抗体であるリツキシマブなどの免疫抑制剤は、ステロイドが不十分な難治性の症例で有望視されています。さらに、補体阻害剤や赤血球破壊に関与する経路を特異的に標的とする低分子薬剤などの新規治療法も検討されています。これらの技術革新は治療の幅を広げ、AIHAのより良い管理に希望をもたらしています。

AIHA治療薬市場の成長は、標的療法の進歩、診断意識の向上、自己免疫疾患の有病率の上昇など、いくつかの要因によって牽引されています。バイオテクノロジーの技術進歩により、モノクローナル抗体や新規免疫調節薬など、より効果的で特異的な治療法の開発が可能になり、患者の転帰が改善されています。認知度の向上と診断技術の改善により、AIHAの早期かつ正確な発見が可能となり、タイムリーな介入とより良い疾患管理が促進されています。さらに、自己免疫疾患の世界の有病率の上昇が、治療を必要とする患者数の増加に寄与しています。製薬会社は、この分野におけるアンメット・メディカル・ニーズの認識の高まりに後押しされ、新たな治療法を市場に投入するための研究開発に投資しています。これらの要因がAIHA治療薬市場の拡大を後押しし、患者や医療提供者に新たな希望をもたらしています。

調査対象企業の例（全56件）

  • Alkem Laboratories Limited
  • Alnylam Pharmaceuticals, Inc.
  • Alpine Immune Sciences
  • Amneal Pharmaceuticals Inc.
  • Annexon Biosciences
  • Apellis Pharmaceuticals Inc.
  • argenx SE
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Rigel Pharmaceuticals Inc.
  • Sanofi SA;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26626

Global Autoimmune Hemolytic Anemia Therapeutics Market to Reach US$873.7 Million by 2030

The global market for Autoimmune Hemolytic Anemia Therapeutics estimated at US$535.6 Million in the year 2023, is expected to reach US$873.7 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$509.1 Million by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$145.9 Million While China is Forecast to Grow at 11.7% CAGR

The Autoimmune Hemolytic Anemia Therapeutics market in the U.S. is estimated at US$145.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$194.7 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Autoimmune Hemolytic Anemia Therapeutics Market - Key Drivers and Trends Summarized

Autoimmune Hemolytic Anemia (AIHA) therapeutics encompass a range of treatments aimed at managing and alleviating the symptoms of AIHA, a rare condition where the immune system mistakenly attacks and destroys the body's red blood cells. This leads to hemolytic anemia, characterized by fatigue, pallor, shortness of breath, and jaundice. The therapeutic landscape includes corticosteroids, immunosuppressive agents, monoclonal antibodies, and supportive treatments such as blood transfusions. The primary goal of these therapeutics is to reduce the rate of red blood cell destruction, manage the immune response, and address symptoms to improve patient quality of life.

In recent years, the development of AIHA therapeutics has seen significant advancements, driven by a deeper understanding of the disease’s pathophysiology and immune mechanisms. Corticosteroids like prednisone are often the first line of treatment due to their efficacy in reducing inflammation and immune activity. However, long-term use can result in adverse effects, prompting the need for alternative therapies. Immunosuppressive agents such as rituximab, a monoclonal antibody targeting CD20 on B-cells, have shown promise in refractory cases where steroids are insufficient. Additionally, novel therapies are being explored, including complement inhibitors and small molecule drugs that specifically target pathways involved in red blood cell destruction. These innovations are expanding the treatment arsenal and offering hope for better management of AIHA.

The growth in the AIHA therapeutics market is driven by several factors, including advancements in targeted therapies, increased diagnostic awareness, and a rising prevalence of autoimmune disorders. Technological progress in biotechnology has enabled the development of more effective and specific treatments, such as monoclonal antibodies and novel immunomodulatory drugs, which have improved patient outcomes. Increased awareness and improved diagnostic techniques are leading to earlier and more accurate detection of AIHA, facilitating timely intervention and better management of the disease. Additionally, the rising prevalence of autoimmune conditions globally is contributing to a larger patient population requiring treatment. Pharmaceutical companies are investing in research and development to bring new therapies to market, spurred by the growing recognition of unmet medical needs in this area. These factors collectively drive the expansion of the AIHA therapeutics market, offering new hope for patients and healthcare providers.

Select Competitors (Total 56 Featured) -

  • Alkem Laboratories Limited
  • Alnylam Pharmaceuticals, Inc.
  • Alpine Immune Sciences
  • Amneal Pharmaceuticals Inc.
  • Annexon Biosciences
  • Apellis Pharmaceuticals Inc.
  • argenx SE
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Rigel Pharmaceuticals Inc.
  • Sanofi SA;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Autoimmune Hemolytic Anemia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Autoimmune Hemolytic Anemia Drives Demand for Therapeutics
    • Advancements in Diagnostic Technologies Propel Growth in Anemia Therapeutics Market
    • Growing Awareness of Rare Diseases Spurs Demand for Specialized Treatments
    • Innovations in Monoclonal Antibody Therapies Generate Market Interest
    • Expansion of Biopharmaceutical Sector Drives Adoption of Novel Therapies
    • Advances in Immunotherapy Techniques Generate New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Autoimmune Hemolytic Anemia Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • CHINA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • INDIA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION